AI Article Synopsis
- Ivabradine is recommended for patients with heart failure (HF) to lower the risk of cardiovascular death and hospitalization from worsening symptoms, specifically in those with a heart rate over 70 bpm and reduced ejection fraction.
- The study, conducted on 111 HF patients, compared outcomes between those treated with ivabradine and those without; results indicated a lower hospitalization risk for the ivabradine group, although the difference wasn't statistically significant.
- Conclusions show that while ivabradine may reduce hospitalization risk in HF patients, it did not significantly affect the overall mortality rate compared to the standard treatment alone.
Article Abstract
Background: Ivabradine is recommended in heart failure (HF) patients to reduce cardiovascular death and hospitalization due to worsening of HF symptoms.
Aims And Objectives: To study the effect of Ivabradine in addition to guideline-directed medical therapy (GDMT) in a group of HF patients with HR more than 70 bpm, HF with reduced ejection fraction (HFrEF) left ventricular ejection fraction (LVEF ≤ 40%), and New York Heart Association class II-IV.
Methods: The study was conducted at Heart Hospital, Hamad Medical Corporation, Qatar. HF patients with age > 18 years, LVEF ≤40%, on GDMT, and HR of ≥70 bpm were included. The study population was divided into two groups: ivabradine group and non-ivabradine group. The primary outcomes were risk, number and length of hospitalizations due to worsening HF, and cardiovascular mortality. The secondary outcome was all-cause mortality. Baseline characteristics were collected at enrollment. Study outcomes were compared in the two groups by applying Chi-square and Fisher's exact tests. Logistic regression model was applied to assess both hospitalizations and cardiovascular mortality.
Results: A total of 111 patients were studied, 37 (33.94%) ivabradine group and 74 (66.67%) non-ivabradine group. Risk of hospitalization was lower in Ivabradine group compared to non-Ivabradine group (odds ratio: 0.43, 95% confidence interval [CI]: 0.16-1.015, P = 0.094). Average length of hospitalization in ivabradine and non-ivabradine groups was 12.54 and 8.91 days, respectively (incidence rate ratio [IRR]: 1.63, 95% CI: 0.79-3.38, = 0.187). Compared to non-ivabradine, ivabradine patients had lower number of hospitalizations (IRR: 1.13, 95% CI: 0.61-2.11, = 0.694). Death rate in both ivabradine and non-ivabradine groups was 3.
Conclusions: Ivabradine along with GDMT reduces the risk of hospitalization due to worsening HF symptoms. Ivabradine had no significant effect on cardiovascular mortality and all-cause mortality. HFrEF non-Arabs patients have lower risk, number and length of hospitalization, and mortality compared to Arabs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574096 | PMC |
| http://dx.doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_23_20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Clinical Utility of Targeted Heart Rate Control in Septic Shock: A Systematic Review and Meta-analysis of Randomized Controlled Trials with Trial Sequential Analysis.
Indian J Crit Care Med
December 2024
Department of Critical Care Medicine, Ruby Hall Hospital, Pune, Maharashtra, India.
Objectives: Heart rate control using beta-blockers in sepsis has traditionally been avoided because of concerns with worsening cardiac index and organ perfusion. Recent studies has explored the possible beneficial effects of targeted heart rate control in patients with septic shock who have tachycardia despite initial resuscitation. We performed a systematic review and meta-analysis to explore the effects of heart rate control in septic shock patients.
View Article and Find Full Text PDFEvaluation of efficacy of oral ivabradine for attenuation of hemodynamic response to intubation in hypertensive surgical patients: Effect on rate pressure product as an index of myocardial oxygen demand.
J Anaesthesiol Clin Pharmacol
August 2024
Department of Anesthesia, RNT Medical College, Udaipur, Rajasthan, India.
Background And Aims: An exaggerated hemodynamic response to endotracheal intubation is observed in hypertensive patients, and its attenuation proves challenging. The role of oral ivabradine, a unique heart rate-lowering drug with a favorable hemodynamic profile, is not yet studied. The aim of this study was to evaluate the effect of oral ivabradine on the attenuation of hemodynamic response to endotracheal intubation in hypertensive surgical patients assessed by rate pressure product (RPP), which is a very reliable indicator of myocardial oxygen demand.
View Article and Find Full Text PDFEffects of dopamine β-hydroxylase inhibition in pressure overload-induced right ventricular failure.
Pulm Circ
October 2024
Department of Research BIAL, Portela & Cª, S.A. Coronado S. Romão e S. Mamede Portugal.
Activation of the sympathetic nervous system is observed in pulmonary arterial hypertension patients. This study investigates whether inhibiting the conversion of dopamine into noradrenaline by dopamine -hydroxylase (DH) inhibition with BIA 21-5337 improved right ventricular (RV) function or remodeling in pressure overload-induced RV failure. RV failure was induced in male Wistar rats by pulmonary trunk banding (PTB).
View Article and Find Full Text PDFPostural orthostatic tachycardia syndrome after COVID-19 vaccination: A systematic review.
BMC Cardiovasc Disord
November 2024
University Center for Research and Development, Chandigarh University, Mohali, Punjab, India.
Article Synopsis
- The COVID-19 vaccination campaign has successfully reduced severe illness and mortality, but concerns about potential side effects like Postural Orthostatic Tachycardia Syndrome (POTS) have emerged.
- A systematic review examined studies of POTS post-vaccination, with 10 out of 1,531 articles meeting inclusion criteria, involving nearly 285,000 participants.
- Results indicated that while the odds of developing POTS after vaccination are lower compared to post-infection, research is still limited and further studies are necessary.
Cardiac Ablation in the Pediatric Population at a Tertiary Care Center in a Developing Country.
J Cardiovasc Electrophysiol
November 2024
Department of Internal Medicine, Cardiology Division, American University of Beirut Medical Center, Beirut, Lebanon.
Introduction: The aim of this study was to describe our experience and outcome of ablation therapy for arrhythmias in pediatrics at a tertiary care center.
Methods: Data was collected retrospectively from the hospital medical records. All pediatrics presenting to AUBMC between 2000 and 2020 who underwent cardiac ablation were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!